Reference number : GC-2017-Q1-00260, amendment number : , agreement type : G, recipient legal name : Ma, Hongshen (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Collaborative Health Research Projects, program name french : Projets de recherche concertée sur la santé, program purpose english : The vast majority of cancer deaths are caused by metastasis, or the spread of cancer from_x000D_
one part of the body to another. In order for cancer to spread, cells known as circulating tumor_x000D_
cells, must detach from a tumor, circulate in the bloodstream, and reattach to a different_x000D_
tissue. Therefore, circulating tumor cells are considered to be the agents of metastasis that_x000D_
could potentially be used to evaluate the genetic basis of each patients cancer and how they_x000D_
might respond to potential treatments. Genetic analysis of circulating tumor cells is currently_x000D_
limited by the extreme rarity of these cells in the bloodstream, as well as by the differences_x000D_
across individual cells. This project aims to address this challenge by developing a technology_x000D_
to rapidly isolate individual circulating tumor cells for genome sequencing. We will then test_x000D_
this technology by isolating and sequencing single circulating tumor cells from patients with_x000D_
advanced prostate cancer who are currently enrolled in related clinical studies. The genome_x000D_
sequence from single circulating tumor cells will then be compared with other available data in_x000D_
order to determine its value in diagnosis and treatment. Genome sequencing is already being_x000D_
used in some cancers to predict how patients will respond to certain drugs. This project will_x000D_
develop a technology to isolate and sequence cells that are most relevant to metastasis,_x000D_
which will give physicians significantly better information to evaluate each patients disease in_x000D_
order to devise a personalized treatment plan., program purpose french : The vast majority of cancer deaths are caused by metastasis, or the spread of cancer from_x000D_
one part of the body to another. In order for cancer to spread, cells known as circulating tumor_x000D_
cells, must detach from a tumor, circulate in the bloodstream, and reattach to a different_x000D_
tissue. Therefore, circulating tumor cells are considered to be the agents of metastasis that_x000D_
could potentially be used to evaluate the genetic basis of each patients cancer and how they_x000D_
might respond to potential treatments. Genetic analysis of circulating tumor cells is currently_x000D_
limited by the extreme rarity of these cells in the bloodstream, as well as by the differences_x000D_
across individual cells. This project aims to address this challenge by developing a technology_x000D_
to rapidly isolate individual circulating tumor cells for genome sequencing. We will then test_x000D_
this technology by isolating and sequencing single circulating tumor cells from patients with_x000D_
advanced prostate cancer who are currently enrolled in related clinical studies. The genome_x000D_
sequence from single circulating tumor cells will then be compared with other available data in_x000D_
order to determine its value in diagnosis and treatment. Genome sequencing is already being_x000D_
used in some cancers to predict how patients will respond to certain drugs. This project will_x000D_
develop a technology to isolate and sequence cells that are most relevant to metastasis,_x000D_
which will give physicians significantly better information to evaluate each patients disease in_x000D_
order to devise a personalized treatment plan., agreement title english : Development of Technologies for Rapid Isolation and Genome Sequencing of Single Circulating Tumor Cells in Prostate Cancer, agreement title french : Development of Technologies for Rapid Isolation and Genome Sequencing of Single Circulating Tumor Cells in Prostate Cancer, agreement number : CHRPJ, agreement value : 489780.0, agreement start date : 2017-04-25, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2020-2021), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada